Drug Trial Radar · NCT00562315
FACBC PET/CT for Recurrent Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jun 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Oct 2007
Primary completion
Jul 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- David M. Schuster, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Nov 22, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- Single (investigator)
- Primary purpose
- Diagnostic
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypothesis:Anti-\[18F\]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients. This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called \[18\]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called \[18\]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called \[18\]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done. Anti-\[18F\]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention. This study will look at how the \[18\]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.
Conditions
- Prostate Cancer
Interventions
FACBCDrug
Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
ProstaScinctOther
ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With True Positive Scans Within the Prostate BedTime frame: Up to 5 years
- Number of Participants With False Positive Scans Within the Prostate BedTime frame: Up to 5 years
- Number of Participants With True Negative Scans Within the Prostate BedTime frame: Up to 5 years
- Number of Participants With False Negative Scans Within the Prostate BedTime frame: Up to 5 years
- Number of Participants With True Positive Scans Outside the Prostate BedTime frame: Up to 5 years
- Number of Participants With True Negative Scans Outside the Prostate BedTime frame: Up to 5 years
- Number of Participants With False Positive Scans Outside the Prostate BedTime frame: Up to 5 years
- Number of Participants With False Negative Scans Outside the Prostate BedTime frame: Up to 5 years
- Diagnostic Performance of Anti-[18F]FACBC PET-CT Imaging in Detection of Extra-prostatic Recurrence of Prostate CarcinomaTime frame: Up to 5 years
- Diagnostic Performance of Anti-[18F]FACBC PET-CT Imaging in Detection of Recurrent Prostate Carcinoma in the Prostate BedTime frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory University Hospital
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.